Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
Chronic myeloid leukemia: First-line drug of choice
Elias Jabbour
Leukemia
Research output
:
Contribution to journal
›
Article
›
peer-review
58
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Chronic myeloid leukemia: First-line drug of choice'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
100%
Protein-Tyrosine Kinases
86%
Imatinib Mesylate
54%
Pharmaceutical Preparations
39%
Decision Making
26%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
22%
Dasatinib
21%
Survival
17%
Standard of Care
15%
Treatment Failure
15%
Comorbidity
12%
Costs and Cost Analysis
9%
Population
6%